Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care

Autor: Lindsey E Smith, Anu Osinusi, Richard Haubrich, Joel E. Gallant, Katherine K. Perez, Diana M. Brainard, Alex Soriano Viladomiu, Jihad Slim, Lijie Zhong, Anand P Chokkalingam, Robert L. Gottlieb, Nirav Shah, Alan S. Go, Robertino Mera-Giler, Jose I Bernardino, Helena Diaz-Cuervo, Holly Edgar, Tak Yin Owen Tsang, I-Heng Lee, Theresa L. Walunas, Philip A. Robinson, Chloé Phulpin, Shamim M Ali, Hao Hu, Susan Olender, Bindu Balani, Eboni G. Price-Haywood, B Nebiyou Bekele, BumSik Chin, Stéphane De Wit, Su Wang, Shobha Swaminathan, Lanjia Lin

Publikováno v: Clinical Infectious Diseases
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Background We compared the efficacy of the antiviral agent, remdesivir, versus standard-of-care treatment in adults with severe coronavirus disease 2019 (COVID-19) using data from a phase 3 remdesivir trial and a retrospective cohort of patients with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d8552ad50ba5b4036ca6ac52d686c4b